Physician profile
Frank Beardell
NPI 1245235712
$1,698.44
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,132 · 2020: $566.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $292.01 | 2019-2020 | |
| Genzyme Corporation | $133.67 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $119.22 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $102.08 | 2019 | |
| Amgen INC. | $99.62 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $97.05 | 2019-2020 | |
| Celgene Corporation | $94.82 | 2019 | |
| Alexion Pharmaceuticals, INC. | $78.45 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $76.64 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.80 | 2019-2020 | |
| Abbvie INC. | $55.28 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $52.15 | 2019-2020 | |
| Pfizer INC. | $50.13 | 2019-2020 | |
| Genentech USA, INC. | $46.08 | 2019-2020 | |
| Kite Pharma, INC. | $45.76 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $38.37 | 2019 | |
| Jazz Pharmaceuticals INC. | $37.55 | 2019-2020 | |
| Daiichi Sankyo INC. | $32.06 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $30.02 | 2019 | |
| Incyte Corporation | $23.92 | 2020 | |
| Aurobindo Pharma USA, INC. | $19.97 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.45 | 2020 | |
| Gilead Sciences, INC. | $16.78 | 2019 | |
| Agios Pharmaceuticals, INC. | $16.71 | 2020 | |
| Eusa Pharma (US) LLC | $16.69 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.29 | 2020 | |
| Partner Therapeutics, INC. | $14.96 | 2019 | |
| Rigel Pharmaceuticals, INC. | $14.91 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Beardell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.